Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Nat Commun. 2021 Nov 8;12(1):6450. doi: 10.1038/s41467-021-26806-7.
Nat Commun. 2021.
PMID: 34750392
Free PMC article.
Clinical Trial.